OSCR
Oscar Health, Inc.
OSCR has the edge over RCUS overall, supported by stronger fundamentals and stronger modeled upside.
RCUS
Arcus Biosciences, Inc.
RCUS has slightly lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RCUS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
RCUS's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RCUS PE Valuation
RCUS has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RCUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RCUS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RCUS on earnings quality, reporting a profit while its opponent remains loss making.
RCUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.62 | -$0.18 |
| Q2 2026 | -$3.89 | -$0.72 |
| Q1 2026 | -$3.17 | +$1.02 |
| Q4 2025 | -$3.29 | -$0.19 |
| Q3 2025 | -$3.44 | -$0.29 |
| Q2 2025 | -$3.17 | -$0.08 |
| Q1 2025 | -$4.19 | -$1.08 |
| Q4 2024 | -$3.10 | +$1.05 |
RCUS lost $3.62 per share over the past year, about the same as its loss the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RCUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RCUS on profitability, with a higher operating margin.
RCUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9M | -65% |
| Q2 2026 | $41M | -74% |
| Q1 2026 | $17M | -39% |
| Q4 2025 | $33M | +27% |
| Q3 2025 | $26M | -46% |
| Q2 2025 | $160M | +310% |
| Q1 2025 | $28M | -81% |
| Q4 2024 | $26M | -16% |
RCUS's revenue has slid since its 2021 peak: $9M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1456% | -909 points |
| Q2 2026 | -234% | -229 points |
| Q1 2026 | -788% | -353 points |
| Q4 2025 | -345% | +51 points |
| Q3 2025 | -546% | -327 points |
| Q2 2025 | -5% | +267 points |
| Q1 2025 | -436% | -425 points |
| Q4 2024 | -396% | -103 points |
RCUS's operating margin was −1456% last quarter, down 909 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RCUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
RCUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$88M | +$9M |
| Q2 2026 | -$119M | +$14M |
| Q1 2026 | -$138M | -$5M |
| Q4 2025 | -$121M | -$20M |
| Q3 2025 | -$97M | -488% |
| Q2 2025 | -$133M | -$39M |
| Q1 2025 | -$133M | -$127M |
| Q4 2024 | -$101M | -$7M |
RCUS has burned cash in almost every quarter: −$466M over the past year, against −$464M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RCUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1.3M shares |
| 1 year | +20% | +20.9M shares |
| 3 years | +71% | +52.8M shares |
| 5 years | +82% | +57.3M shares |
| Available history | +189% | +83.3M shares |
RCUS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RCUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -2.7x | Net Cash |
| Q2 2022 | -3.8x | Net Cash |
| Q1 2022 | -8.5x | Net Cash |
| Q4 2021 | -2.6x | Net Cash |
RCUS has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RCUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.2 | Neutral |
| Stochastic | 4.6 | Oversold |
RCUS's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RCUS PE vs Healthcare Sector
| Metric | RCUS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RCUS has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RCUS on trend strength, trading above more of its moving averages.
RCUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.1 | 16% below |
| 20 week MA | $25.5 | 30% below |
| 50 week MA | $23.9 | 26% below |
| 100 week MA | $18.0 | 1.1% below |
| 200 week MA | $17.8 | 0.1% above |
RCUS has fallen below most of its moving averages, though it's still 0.1% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RCUS on returns for 2026, with the stronger performance.
RCUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $30.6 | +187% |
| 2021 | $30.6 | $44.6 | +46% |
| 2022 | $44.6 | $20.4 | -54% |
| 2023 | $20.4 | $19.1 | -6.4% |
| 2024 | $19.1 | $15.3 | -20% |
| 2025 | $15.3 | $23.1 | +51% |
| 2026 YTD | $23.1 | $17.8 | -23% |
RCUS's yearly returns have swung widely, from +187% in 2020 to −54% in 2022. It's down 23% so far in 2026.